BBIO vs LYFT · rev $221.9M vs P/E 108, rev $5.79B
BridgeBio Pharma Inc (BBIO) versus LYFT Inc (LYFT) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
LYFT Inc (LYFT) is a software - application company listed on US. It is led by David Risher.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported LYFT revenue for 2024-12-31 was $5.79B. Net income was $22.8M. Revenue was up 31.4% from 2023-12-31 to 2024-12-31. LYFT currently screens at market cap $6.79B and trailing P/E 107.7.
BBIO currently screens at market cap $13.24B. LYFT currently screens at market cap $6.79B and trailing P/E 107.7.
Not investment advice. Open the BBIO and LYFT stock pages for the full models.
Not investment advice.